Panasonic: Verification of inhibitory effect of nanoe™ X, technology with the benefits of hydroxyl radicals on novel coronavirus (SARS-CoV-2)
Panasonic today announced that, in collaboration with the global contract research organization Texcell*1, Texcell has verified the inhibitory effect of the nanoe™ X, technology with the benefits of hydroxyl radicals on the novel coronavirus (SARS-CoV-2).
nanoe™ X, the original ionizer to generate “nano-sized atomized water particles” is developed by Panasonic. It is an electrostatic atomization technology, that collects invisible moisture in the air and applies high voltage to it to produce “hydroxyl radicals contained in water”. The decisive factor is the existence of hydroxyl radicals inside nanoe™ X. Hydroxyl radicals are characterized by being strongly oxidative and highly reactive.
Panasonic has been conducting research on this technology since 1997, and has verified its effectiveness in a variety of areas, including inhibiting certain pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*2.
In 2012, Panasonic conducted a virus clearance test with a third-party organization and confirmed the effectiveness of each of the four categories in terms of biological characteristics. Based on this result, Panasonic announced that "hydroxyl radicals contained in water" technology could be expected to have an inhibitory effect on new viruses*3.
The novel coronavirus (SARS-CoV-2) of the current global pandemic is one such new type of virus and testing with Texcell has now confirmed that the nanoe™ X does have an inhibitory effect on this virus. This testing was carried out in a closed laboratory environment and was not designed to assess its efficacy in uncontrolled living spaces.
Panasonic will continue to pursue the potential of nanoe™ X technology to address possible risks associated with air pollution such as new pathogenic microorganisms, with the aim of creating cleaner environments for people around the world.
For reference :
Testing of inhibitory effect of nanoe™ X on the novel coronavirus (SARS-CoV-2)
・ Overview
A comparative verification was conducted in a 45L test space containing the novel coronavirus (SARS-CoV-2) with and without exposure to nanoe™ X.
・ Results
Over 99.99% of novel coronavirus (SARS-CoV-2) activity was inhibited within 2 hours.
Note: This verification was designed to generate basic research data on the effects of nanoe™ X on the novel coronavirus in laboratory conditions different from those found in living spaces. It was not designed to evaluate product performance.
・ Methodology and data
Organisation :Texcell
Subject :Novel coronavirus (SARS-CoV-2)
Device :nanoe™ X device
Method:
- nanoeTM X device is installed at 15cm from the floor in the 45L test space.
- A piece of gauze saturated SARS-CoV-2 virus solution was placed in a petri dish and exposed to nanoeTM X for a predetermined time.
- The virus infectious titer was measured and used to calculate the inhibition rate.
・ Results data
|
Test subject |
Inhibition rate* |
Capacity |
Hours |
|
SARS-CoV-2 |
99.99% |
45L |
2 hours |
Notes:
*1: Texcell is a global contract research organization that specializes in viral testings, viral clearance, immunoprofiling and R&D or GMP cell banking, for your R&D, GClP, GLP and GMP projects.
With more than 30 years of experience and roots within the Pasteur Institute in Paris, Texcell has a long recognized expertise in viral testing with a broad range of protocols for the detection of adventitious agents.
Texcell is the first spin-off of the Pasteur institute of Paris created in 1997.
*2: Main releases on verification cases
- May 12, 2009:Positive effects of charged water particles on viruses, bacteria, and agricultural chemicals have been verified.
- October 20, 2009: The new influenza virus inhibition effect of charged water particles has been verified.
- February 20, 2012:Suppression effect of charged water particles on pet-related allergens, bacteria, fungi, and viruses have been verified.
- January 16, 2014:Nano-sized electrostatic atomized water particles effectively breaks down PM2.5 components and inhibits growth of fungi attached to Yellow Sand.
*3: January 26, 2012: Virus suppression effect of charged water particles has been verified by the virus clearance test. Co-verified with Charles River Biopharmaceutical Services GmbH, a German testing organization.
About Panasonic
Panasonic is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers.
https://www.panasonic.com/global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005047/en/
Contact information
Media Contact:
Tanya.houston@wildwoodpr.com
Tel: +44 (0) 1293 851115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
